Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094192 | 0.78 | RAB9A (0.35) | SOAT2SOAT1PDK2 | |
| SCHEMBL6094196 | 0.72 | RAB9A (0.34) | SOAT2SOAT1 | |
| SCHEMBL4866722 | 0.69 | POLB (0.36) | SOAT2SOAT1 | |
| SCHEMBL4873285 | 0.68 | PARP1 (0.38) | SOAT2SOAT1 | |
| SCHEMBL4876330 | 0.68 | POLB (0.37) | SOAT2SOAT1 | |
| SCHEMBL4870498 | 0.68 | SOAT2 (0.41) | SOAT2SOAT1 | |
| SCHEMBL4874000 | 0.66 | KMT2A (0.37) | — | |
| SCHEMBL4875888 | 0.66 | L3MBTL1 (0.48) | SOAT2SOAT1 | |
| SCHEMBL7091821 | 0.66 | PLA2G2A (0.41) | SOAT2SOAT1PDK2 | |
| SCHEMBL4873890 | 0.66 | SMN1; SMN2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | SOAT2 2253/4885SOAT1 2137/4885PDK2 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.